Asset
RELMAPIRAZIN
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04109482 | phase1_2 | terminated | 2020-02-17 | 2023-05-17 | Mustang Bio | Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN. |
FDA applications (0)
This company has no applications containing this asset.